Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Amortizatization of Intangibles (2022 - 2025)

Fennec Pharmaceuticals filings provide 4 years of Amortizatization of Intangibles readings, the most recent being -$12000.0 for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 101.63% to -$12000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $65000.0, a 91.88% decrease, with the full-year FY2025 number at $65000.0, down 91.88% from a year prior.
  • Amortizatization of Intangibles hit -$12000.0 in Q4 2025 for Fennec Pharmaceuticals, down from $26000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $736000.0 in Q4 2024 to a low of -$685000.0 in Q3 2024.
  • Median Amortizatization of Intangibles over the past 4 years was $15000.0 (2022), compared with a mean of $63200.0.
  • The widest YoY moves for Amortizatization of Intangibles: up 4806.67% in 2024, down 3705.26% in 2024.
  • Fennec Pharmaceuticals' Amortizatization of Intangibles stood at $15000.0 in 2022, then changed by 0.0% to $15000.0 in 2023, then surged by 4806.67% to $736000.0 in 2024, then tumbled by 101.63% to -$12000.0 in 2025.
  • The last three reported values for Amortizatization of Intangibles were -$12000.0 (Q4 2025), $26000.0 (Q3 2025), and $38000.0 (Q2 2025) per Business Quant data.